HighTower Trust’s Teva Pharmaceuticals TEVA Stock Holding History

HighTower Trust’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-13,000	Closed	-$280K	–	112
2018 Q3	$280K	Sell	13,000 -4,500	-26%	-$104K	0.03%	96
2018 Q2	$426K	Hold	17,500	–	–	0.05%	105
2018 Q1	$299K	Hold	17,500	–	–	0.04%	105
2017 Q4	$332K	Hold	17,500	–	–	0.04%	103
2017 Q3	$308K	Buy	17,500 +8,000	+84%	+$180K	0.04%	83
2017 Q2	$316K	Buy	9,500 +3,000	+46%	+$92.9K	0.04%	115
2017 Q1	$208K	Buy	+6,500	New	+$222K	0.02%	152

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

HighTower Trust's TEVA Position: Q4 2018 in Review

HighTower Trust sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 13,000 shares — an estimated $280K sold.

HighTower Trust first reported a position in TEVA in Q1 2017 and held it in 7 quarters. The position peaked at $426K in Q2 2018. 551 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

HighTower Trust reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
HighTower Trust sold 13,000 Teva Pharmaceuticals shares in Q4 2018, an estimated $280K.
HighTower Trust first reported a position in Teva Pharmaceuticals in Q1 2017 and held it in 7 quarters.
HighTower Trust's Teva Pharmaceuticals position peaked at $426K in Q2 2018.
551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on HighTower Trust's 13F filing for Q4 2018, filed 28 Jan 2019.